Business Context and Reporting Period
Company: Alpha Pro Tech, Ltd.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2003
Business Overview: The Company manufactures and distributes disposable protective apparel, infection control products (masks, shields), extended care products, and consumer products (pet beds). Primary markets include pharmaceutical, medical, dental, industrial safety, and cleanroom sectors, predominantly in the United States.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2003 |
|---|---|---|
| Sales | $6,517,000 | $20,467,000 |
| Gross Margin | $3,218,000 (49.4%) | $10,719,000 (52.4%) |
| Net Income | $701,000 | $2,529,000 |
| Diluted EPS | $0.03 | $0.11 |
| Cash and Equivalents | $3,180,000 (as of Sep 30, 2003) | |
| Working Capital | ||
| Debt | $0 (Debt-free as of Sep 30, 2003) | |
| Operating Cash Flow (9mo) | $1,025,000 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 30.0% ($1.5M) for the quarter and 27.8% ($4.4M) for the nine months compared to the prior year periods.
- Profitability: Net income surged 93.7% for the quarter and 74.3% for the nine months. Income from operations increased 71.4% (quarter) and 76.5% (nine months).
- Segment Performance:
- Apparel: Sales up 21.5% (quarter) driven by pharmaceutical industry growth, offset by weakness in the electronics sector.
- Mask and Shield: Sales up 69.0% (quarter) and 112.3% (nine months). Growth was significantly driven by SARS-related N-95 mask and eye shield sales (approx. $0.5M in Q3 and $3.5M total since April 2003).
- Extended Care: Sales declined 7.5% (quarter) and 11.3% (nine months) due to decreased pet bed sales.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 14.6% (quarter) and 17.3% (nine months), primarily due to hiring additional sales personnel and increased commissions. However, SG&A as a percentage of sales decreased.
- Debt Reduction: The Company paid off all notes payable during the period and is currently debt-free.
Outlook, Risks, and Management Commentary
- SARS Impact: Management notes that while SARS-related sales have decreased since Q2, heightened awareness of infection control is expected to sustain demand for N-95 masks and protective gear. The Company has increased inventory and production capacity in anticipation of potential future outbreaks.
- Strategic Initiatives: The Company implemented a strategy to communicate directly with end-users and expanded its sales team from 9 to 13 personnel (total team of 22 by period end). Management expects this to drive continued market share growth.
- Liquidity: The Company maintains a $3.5M credit facility with $3.12M available borrowing capacity. Management believes cash from operations and the credit facility are sufficient for future working capital and capital expenditures.
- Share Repurchases: The Company repurchased 300,000 shares for $287,000 during the nine-month period. Cumulative buybacks since 1999 total 2.1M shares for $2.1M.
- Risks: Potential negative impact from foreign currency exchange rate fluctuations (manufacturing in Mexico and China) and the uncertainty of SARS resurfacing. The Company does not hedge these risks.
Investor Verification Checklist
- SARS Sales Sustainability: Verify the extent to which Q3 and YTD growth is attributable to temporary SARS-related demand versus core business growth (management estimates 20% core growth).
- Inventory Levels: Review the significant increase in inventory ($2.25M increase in nine months) to ensure it aligns with demand forecasts and does not indicate obsolescence risk.
- Pharmaceutical Sector Exposure: Confirm the stability of the new revenue streams from the pharmaceutical industry which offset declines in the electronics sector.
- Debt-Free Status: Confirm the elimination of all notes payable and the terms of the unused $3.5M credit facility.
- SG&A Efficiency: Monitor whether the increased sales force yields sustained revenue growth to justify the higher payroll and commission expenses.